Regulation of intestinal UGT1A1 by the FXR agonist obeticholic acid (OCA) is controlled
by CAR through intestinal maturation

André A. Weber¹, Elvira Mennillo¹, Xiaojing Yang¹, Lori W.E. van der Schoor², Johan W.
Jonker², Shujuan Chen¹, Robert H. Tukey¹,*

¹Laboratory of Environmental Toxicology, Department of Pharmacology, University of California,
San Diego, La Jolla, CA 92093, USA.

²Center for Liver, Digestive and Metabolic Diseases, Department of Pediatrics, University of
Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.

Address correspondence to: Robert H. Tukey, Department of Pharmacology, University of
California, San Diego 92093-0722. E-mail: rtukey@health.ucsd.edu
Running title page

Running title: CAR activation by OCA induces UGT1A1 and IEC maturation

Corresponding author:
Robert H. Tukey, Department of Pharmacology, University of California, San Diego 9500 Gilman Drive, La Jolla, California, 92093-0722. E-mail: rtukey@health.ucsd.edu

Text pages: 16 (Abstract – Discussion, not including references and figure legends)
Tables: 1
Figures: 7
Supplemental figures: 2
Abstract: 245
Introduction: 527
Discussion: 1115

Abbreviations
AhR, aryl hydrocarbon receptor; Akp3, alkaline phosphatase 3; CAR, constitutive androstane receptor; Cyp, cytochrome P450, Cyp7a1, Cholesterol 7 alpha-hydroxylase; DAPT, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; FGF15, fibroblast growth factor 15; FXR, farnesoid X receptor; Glb1, galactosidase beta 1; IEC, intestinal epithelium cell; Krt20, keratin 20; Lrp2, Low density lipoprotein-related protein 2; NCoR1, nuclear receptor corepressor 1; Nqo-1, NAD(P)H dehydrogenase [quinone] 1; Nox4, NADPH oxidase 4; Nrf2, Nuclear factor erythroid 2-related factor 2; OCA, obeticholic acid; PXR, pregnane X receptor; PPARα, peroxisome proliferator-activated receptor alpha; Shp, small heterodimer partner; SI, small intestine; Sis, sucrase isomaltase; TSB, total serum bilirubin; UGT, UDP-glucuronosyltransferase
Abstract

UDP-glucuronosyltransferase 1A1 (UGT1A1) is the only transferase capable of conjugating serum bilirubin. However, temporal delay in the development of the UGT1A1 gene leads to an accumulation of serum bilirubin in newborn children. Neonatal humanized UGT1 mice (hUGT1), which accumulate severe levels of total serum bilirubin (TSB), were treated by oral gavage with obeticholic acid (OCA), a potent FXR agonist. OCA treatment led to dramatic reduction in TSB levels. Analysis of UGT1A1 expression confirmed that OCA induced intestinal and not hepatic UGT1A1. Interestingly, Cyp2b10, a target gene of the nuclear receptor CAR, was also induced by OCA in intestinal tissue. In neonatal hUGT1/Car−/− mice, OCA was unable to induce CYP2B10 and UGT1A1, confirming that CAR and not FXR is involved in the induction of intestinal UGT1A1. However, OCA did induce FXR target genes like Shp in both intestines and liver with induction of Fgf15 in intestinal tissue. Circulating FGF15 activates hepatic FXR and together with hepatic Shp blocks Cyp7a1 and Cyp7b1 gene expression, key enzymes in bile acid metabolism. Importantly, the administration of OCA in neonatal hUGT1 mice is accelerating intestinal epithelial cell maturation, which directly impacts on induction of the UGT1A1 gene and the reduction in TSB levels. Accelerated intestinal maturation is directly controlled by CAR, since induction of enterocyte marker genes Sis, Akp3 and Krt20 by OCA does not occur in hUGT1/Car−/− mice. Thus, new findings link an important role for CAR in intestinal UGT1A1 induction and its role in the intestinal maturation pathway.
Significance statement

Obeticholic acid (OCA) activates FXR target genes in both liver and intestinal tissues while inducing intestinal UGT1A1 which leads to the elimination of serum bilirubin in *hUGT1* mice. However, the induction of intestinal UGT1A1 and the elimination of bilirubin by OCA is driven entirely by activation of intestinal CAR, and not FXR. The elimination of serum bilirubin is based on a CAR dependent mechanism that facilitates the acceleration of IEC differentiation, an event that underlies the induction of intestinal UGT1A1.
Introduction

Humanized *UGT1* (h*UGT1*) mice express the entire human *UGT1* locus (9-*UGT1* genes) in a *Ugt1*-null background and have served as an excellent animal model to examine the underlying processes linking important developmental events with gene expression (Fujiwara et al., 2010). One of the more significant events is the delayed developmental expression of the *UGT1A1* gene, which is solely responsible for the metabolism of serum bilirubin (Fujiwara et al., 2012). Like the hepatic expression patterns in newborns, the *UGT1A1* gene is developmentally delayed in newborn neonatal mice, resulting in the accumulation of severe levels of serum bilirubin. In humans, most cases of hyperbilirubinemia in children are benign except when the rapid onset of severe neonatal hyperbilirubinemia (SNH) is not monitored or prevented (Chen and Tukey, 2018). Major risk factors that lead to the onset of SNH include accelerated hemolysis brought on by Rhesus disease and ABO incompatibility, glucose-6-phosphate dehydrogenase (G6PD) deficiency, infections, in addition to breast feeding and premature birth (Bhutani et al., 2013; Maisels, 2015; Olusanya et al., 2015; Wong and Stevenson, 2015; Cunningham et al., 2016). Extreme levels of TSB can lead to early or acute bilirubin encephalopathy (ABE), presented early as lethargy and poor feeding, but can progress to hypo- and hypertonia, high-pitched crying, muscle spasms, opisthotonos, seizures, and even death (Bhutani and Johnson-Hamerman, 2015). The more chronic form, which proceeds ABE, is termed kernicterus (Kaplan et al., 2011). In approximately 10% of newborn *hUGT1* mice, SNH develops that leads to spontaneous seizures and death (Chen and Tukey, 2018). One of the CNS patterns that develops in these mice is a dramatic reduction in nerve myelination, an event that we had speculated contributes to the seizure pattern (Barateiro et al., 2016). The human *UGT1A1* gene is regulated by events that leads to activation of the pregnane-X-receptor (PXR) (Chen et al., 2012), constitutive androstane receptor (CAR) (Yoda et al., 2017; Paszek and Tukey, 2020), and the peroxisome proliferator receptor α (PPARα) (Senekeo-Effenberger et al., 2012).
2007), followed by induction of the UGT1A1 gene in either the liver or intestines. Induction of UGT1A1 in neonatal hUGT1 mice results in a precipitous drop in serum bilirubin levels, thus serving as an excellent animal model to screen and test therapeutics that could be used to treat infants with SNH (Chen and Tukey, 2018). The challenge is to identify agents that do not share toxicities when administered to humans.

An exciting class of drugs that is being investigated for a number of liver and biliary abnormalities are selective farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA). Obeticholic acid has been studied in conditions such as primary biliary cholangitis (PBC) with beneficial effects while also displaying a capacity to reduce total serum bilirubin (TSB) levels (Parés et al., 2020). While OCA is an effective agonist for the activation of FXR, there is no evidence that activated FXR targets the UGT1A1 gene. To examine this possibility in greater detail, experiments have been conducted in neonatal hUGT1 mice treated orally with OCA, with the surprising result that treatment dramatically lowers TSB levels. However, our findings clearly indicate that induction of UGT1A1 by OCA is not a result of FXR targeting the UGT1A1 gene.
Material and Methods

Chemical reagents

Obeticholic acid (OCA) was obtained from MedChemExpress (South Brunswick, NJ) and DAPT from Sigma Aldrich (Saint Louis, MO). ORA-Plus oral suspension solution from Perrigo (Allegan, MI). Antibodies used for Western Blotting were: anti-UGT1A1 (Ab-170858) and anti-CYP7A1 (Ab-65596) from Abcam, anti-GAPDH (sc-32233), anti-FGF15 (sc-514647) and anti-SIS (sc-27603) from Santa Cruz Technologies, anti-CYP2B10 (a kind gift from Dr. Masahiko Negishi, NIEHS), anti-mouse IgG horseradish peroxidase (HRP) conjugated antibody and anti-rabbit IgG HRP conjugated antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA) and anti-goat IgG horseradish peroxidase (HRP) conjugated antibody from Jackson Immunoresearch (West Grove, PA).

Animals

Transgenic mice expressing the human UGT1 locus in a Ugt1⁻/⁻ background (hUGT1) were developed previously (Fujiwara et al., 2010). The Car-null (Car⁻/⁻) mice was a gift from Dr. Masahiko Negishi (National Institute of Environmental Health Sciences) and crossed with hUGT1 mice to generate hUGT1/Car⁻/⁻ mice (Fujiwara et al., 2012). All animals were housed at the University of California San Diego (UCSD) Animal Care Facility and received food and water ad libitum. The protocols for mouse handling and all procedures were approved by the UCSD Animal Care and Use Committee (IACUC), and these protocols were conducted in accordance with federal regulations. Neonatal 10-day-old hUGT1 or hUGT1/Car⁻/⁻ were treated by oral gavage with ORA-Plus (vehicle) or 50 mg/kg/day OCA divided into two doses per day (25 mg/kg each). After five consecutive days, neonatal mice (n=3-4 per group) were sacrificed and blood, livers and small intestines collected.
**Bilirubin measurements**

Blood from neonates was obtained from the submandibular vein, collected into an Eppendorf tube, and centrifuged at 14,000 × g for 2 min. A small sample of serum was used to measure total serum bilirubin (TSB) levels using a Unistat Bilirubinometer (Reichert, Inc., Depew, NY).

**Isolation of Crypt Cells and Organoid Culture**

Intestinal crypt cell isolation and organoid culturing were carried out according to previous publications with several modifications (Sato et al., 2009; Sato and Clevers, 2013). Briefly, mouse small intestine was dissected, cut longitudinally, and washed with ice-cold Dulbecco’s phosphate-buffered saline (DPBS). The tissue was further dissected into small pieces and incubated in DPBS containing 2 mM EDTA at 4°C shaking for 30 minutes. Then, EDTA solution was washed out and 10% fetal bovine serum in DPBS buffer was added followed by vigorously shaking to release villi and crypt cells. The cell solution was filtered through a 70 mm cell strainer. The filtrate was centrifuged at 1000 g for 7 minutes at 4°C, and the cell pellet was resuspended in DPBS. Crypt cells were counted. Approximately 1000 crypts were suspended into 50 μl ice-cold Matrigel and plated into prewarmed 24-well culture plate. Twenty minutes after the incubation at 37°C, 0.5 ml of complete growth medium (advanced DMEM with GlutaMax, Hepes, penicillin/streptomycin, N2 and B27 supplements, with 2.5 mM N-acetylcysteine, 0.1 mg/ml mouse Noggin, 0.05 mg/ml mouse EGF, and 10% of R-Spondin1-conditioned medium) was added. The growth of organoids was monitored. Mouse EGF was added every other day. Fresh medium was added every 3 days. Cells were normally ready for passage every 4-5 days. Crypt cells were exposed to various concentration of OCA (50 and 100 μM) and to DAPT (10 μM), a known intestinal maturation inductor, as a positive control (Ogaki et al., 2013) on day 3 and after 24 hours, the cells were collected in triplicate for further analysis.
Reverse Transcription Quantitative-PCR

Tissue samples were homogenized in 1mL TRIzol Reagent (Thermo Fisher Scientific) and total RNA from whole tissues was isolated. Using iScript Reverse Transcriptase (Bio-Rad Laboratories, Hercules, CA), 1 μg of total RNA was used for the generation of cDNA in a total volume of 12 μL as outlined by the manufacturer. Following cDNA synthesis, quantitative (real time) PCR was carried out on a CFX96 qPCR system (BioRad) using SsoAdvanced SYBR Green Supermix (BioRad). All primers used in this study are reported in Table 1.

Western blot analysis

For whole tissue analyses, minced liver tissue (0.1 mg) were homogenized in 0.4 mL 1X RIPA lysis buffer (EMD Millipore, Billerica, MA) supplemented with protease and phosphatase inhibitor cocktail (Sigma-Aldrich). The samples were centrifuged at 16,000g for 20 min at 4°C and the supernatants were transfer to a new tube and kept at -80°C until analysis. Proteins were quantified using bovine serum albumin (BSA) as standard.

Western blots were performed by using NuPAGE 4–12% BisTris-polyacrylamide gels (Invitrogen) with the protocols described by the manufacturer. Protein (30 μg) was subject to electrophoresis at 170 V for 60 min and transferred at 20 V for 60 min to PVDF membranes (EMD Millipore). Membranes were blocked with 5% non-fat milk at room temperature for 1 hour and incubated with primary antibodies, at 4 °C overnight. Membranes were then washed and exposed to HRP-conjugated secondary antibodies (anti-mouse IgG, anti-rabbit IgG and anti-goat IgG) for 1 hour at room temperature. Protein was detected by the ECL Plus Western blotting detection system (BioRad) and was visualized by the BioRad Chemidoc Touch Imaging System.

Statistical analyses

Data are represented as mean ± SD. Statistical differences were determined by Student’s t-test. P values <0.05 were considered statistically significant, and these differences
are indicated with *$P<0.05$; **$P<0.01$; ***$P<0.001$. Statistical analyses were performed using GraphPad 5 (San Diego, CA).
Results

Treatment of OCA in neonatal hUGT1 mice

Our laboratory previously reported that UGT1A1 can be transcriptionally induced by several nuclear receptors like PXR (Chen et al., 2012), CAR (Yoda et al., 2017; Paszek and Tukey, 2020), peroxisome proliferator-activated receptor alpha (PPARα) (Senekoe-Effenberger et al., 2007), liver X receptor alpha (LXRα) (Hansmann et al., 2020), the environmental sensors aryl hydrocarbon receptor (AhR) (Yueh et al., 2003), nuclear factor erythroid-2 related factor 2 (Nrf2) (Yueh and Tukey, 2007; Yoda et al., 2017) and following activation of the IKK/NFκB pathway (Liu et al., 2016). A recent clinical report suggested that obeticholic acid (OCA) treatment, an FXR activator, lowers serum bilirubin levels (Parés et al., 2020). However, confirmation that FXR played a role in the lowering of bilirubin was not apparent, and there is no existing evidence that FXR can regulate the UGT1A1 gene.

After treatment of hUGT1 mice with OCA, serum bilirubin levels were reduced, indicating that UGT1A1 was induced (Fig. 1A). Analysis of gene and protein expression in small intestine (SI) confirmed a dramatic induction of UGT1A1 (Fig. 1B, C) only, since induction did not occur in liver tissue. This result demonstrates that intestinal UGT1A1 expression is the major regulator of bilirubin clearance in mice treated with OCA (Fig. S1). This does not mean, however, that FXR was not activated. The induction of small heterodimer partner gene (Shp) transcripts and a decrease of Cyp7a1 transcripts and protein levels in the liver of OCA treated neonates confirms that FXR is activated in the liver (Fig. 2A). There are two pathways involved in bile acid metabolism. The classic pathway with the participation of CYP7A1 and the alternate (acidic) pathway with the key enzyme CYP7B1 (Kliewer and Mangelsdorf, 2015). As demonstrated, Cyp7a1 gene expression is decreased in OCA treated mice resulting from inhibition of gene expression by FGF15. Consistent with this, Cyp8b1, a downstream enzyme in the classic pathway, is also decreased. Gene expression analysis also revealed that the alternate pathway is blocked in OCA treated neonatal mice with the down regulation of Cyp7b1 enzyme. Only
CYP27A1, which is an enzyme that participates in both pathways, was not affected by the treatment (Fig. 2B). This result suggests that OCA is affecting both classic and alternate pathways of bile acids metabolism.

The role of CAR in intestinal UGT1A1

Among the target genes of the nuclear receptors or environmental sensors known to regulate UGT1A1, intestinal Cyp2b10, a target gene of activated CAR, was substantially induced by OCA treatment. Along with gene expression, Western blot analysis confirmed strong induction of CYP2B10 in intestines (Fig. 3A). This result indicates a possible role for activated CAR leading to induction of intestinal UGT1A1. A slight increase was also observed for the PXR target gene, Cyp3a11, with no statistical differences to Nrf2, PPARα and AhR target genes (Nqo-1, Cyp4a10 and Cyp1a1, respectively) (Fig. S2).

To examine the possibility that activated CAR is inducing UGT1A1, 10-day-old hUGT1/Car−/− mice were treated by gavage with OCA and analysis of gene expression and protein levels monitored in both liver and SI. TSB levels were not reduced when hUGT1/Car−/− mice were treated with OCA when compared with hUGT1/Car−/− neonatal mice that received only vehicle (Fig. 3B). Also, there was no induction of intestinal UGT1A1 and CYP2B10 in OCA treated hUGT1/Car−/− mice, confirming that CAR plays an important role in inducing intestinal UGT1A1 in mice treated with OCA (Fig. 3C). With this result, the possibility exists that CAR and FXR are working synergistically to induce UGT1A1 and CYP2B10, a property that might impact directly on FXR activation. When we examined FXR target genes, Shp and Fgf15 in intestines were induced in hUGT1 and hUGT1/Car−/− mice treated with OCA (Fig. 4A), while the Cyp7a1 and Shp gene in liver, which is blocked by FGF15, was inhibited in hUGT1 and hUGT1/Car−/− mice, demonstrating that CAR is not involved in cellular cross talk with FXR activation by OCA (Fig. 4B).

OCA accelerates intestinal maturation in a CAR dependent fashion
Since OCA is not a CAR ligand, we elected to examine selective intestinal epithelial cell gene markers that are linked to epithelial cell maturation and proliferation. Several lines of evidence indicate that accelerated intestinal epithelial cell maturation has a direct impact on induction of the intestinal \textit{UGT1A1} gene in \textit{hUGT1} mice (Chen et al., 2017). When the intestinal nuclear receptor corepressor 1 (\textit{Ncor1}) gene was targeted for deletion in \textit{hUGT1} mice, hyperbilirubinemia in neonatal \textit{hUGT1/NCoR1}\textsuperscript{ΔSI} mice was completely diminished (Chen et al., 2017). When we investigated the underlying mechanism leading to induction of intestinal UGT1A1 and reduction in serum bilirubin, it was discovered that NCoR1 deletion induced intestinal epithelial cell (IEC) maturation, as determined by accelerated IEC proliferation along with IEC maturation marker genes that are regulated during the maturation process (Chen et al., 2017; Yoda et al., 2017). Sucrase-isomaltase (SIS) consists of two subunits, sucrase and isomaltase, that form a dimer that is anchored on the brush border to generate glucosidase activity (Wang et al., 2001). SIS only exists in differentiated duodenal and jejunal enterocytes and has been a marker of enterocyte maturation, and is generated as a single polymer that is cleaved forming the two subunits (Hauri et al., 1985). Following oral OCA treatment, induction of the \textit{Sis} gene expression was significantly induced along with induction of SIS protein as demonstrated by Western blot analysis (\textbf{Fig. 5A}). Additional markers of intestinal maturation are alkaline phosphatase 3 (\textit{AKP3}) and jejunal-specific keratin, type I cytoskeletal 20 (\textit{KRT20}). Both intestinal \textit{Akp3} and \textit{Krt20} genes were induced following OCA treatment (\textbf{Fig. 5A}). During maturation, other proteins are downregulated such as NADPH Oxidase 4 (\textit{NOX4}), a protein that is down-regulated at the suckling to weaning transition (Mochizuki et al., 2009; Muncan et al., 2011). Following OCA treatment, the \textit{Nox4} gene is repressed (\textbf{Fig. 5A}). Combined, these findings demonstrate that OCA is accelerating intestinal tissue maturation, a finding previously demonstrated to have a direct impact on expression of intestinal UGT1A1.

OCA induction of intestinal UGT1A1 is CAR dependent. To determine if there is a connection between CAR dependency and the induction of intestinal maturation, the maturation
marker genes were measured in hUGT1/Car+/− neonatal mice following oral administration of OCA. Unlike the induction patterns of these genes in hUGT1 mice, induction of Sis, Akp3, and Krt20 or the downregulation of Nox4 were not regulated in OCA treated hUGT1/Car+/− neonatal mice (Fig. 5B). These findings indicate that OCA induction of intestinal maturation during the neonatal period is CAR dependent.

**Treatment of OCA in organoids**

Sato (Sato et al., 2009) established long-term culture conditions in which one single Lgr5+ stem cell embedded in matrix gel could independently generate villus-like epithelial organoids containing all differentiated IECs that is reminiscent to the normal gut (Sato and Clevers, 2013). We have shown previously that activation of PXR, PPARα, LXR, AhR, and CAR with selective ligands results in downstream targeted gene expression, confirming that the family of nuclear receptors are functional in intestinal crypt organoids (Lu et al., 2017). To determine if OCA is capable of impacting intestinal crypt organoid differentiation in a pattern similar to that observed with intestinal tissue from treated hUGT1 mice, we treated crypt organoid cultures isolated from 12-day old hUGT1 mice with OCA at 50 and 100 µm for 24 hours. The treatment of the organoids at both concentrations showed a robust induction of Shp and Fgf15 gene expression (Fig.6A) with a significant increase in FGF15 protein levels (Fig.6E), indicating that OCA treatment leads to FXR activation. Only at the higher concentration was UGT1A1 gene expression (Fig.6B) and protein levels (Fig.6E) slightly induced with the values being statistically significant. However, unlike the dramatic induction of intestinal Cyp2b10 gene and protein expression by OCA in hUGT1 mice, there was a reduction or inhibition of Cyp2b10 gene expression in organoid cultures. As we demonstrate in Fig. 5, when neonatal hUGT1 mice were treated with OCA, intestinal maturation marker genes Sis and Akp3 were induced consistent with IEC differentiation. However, when crypt organoids were treated with OCA, there was a significant reduction in expression of these maturation marker genes (Fig. 6D). To validate that the organoids were capable of differentiation, they were
exposed to DAPT, a known γ-secretase and Notch signaling inhibitor known to drive IEC differentiation (Ogaki et al., 2013). DAPT had no impact on FXR target genes (Fig. 6A) but led to significant induction of the UGT1A1 and Cyp2b10 genes (Fig. 6B & 6C), confirming that differentiation is sufficient to drive induction of intestinal UGT1A1 gene expression. However, OCA treatment had no impact on crypt organoid differentiation (Fig. 6D). This interesting finding indicates that the actions of OCA on CAR dependent induction of intestinal UGT1A1 and CYP2B10 in neonatal hUGT1 mice engages important cellular mechanisms in vivo linked to intestinal maturation that are absent when these experiments are conducted in 3-dimensional intestinal organoid cultures.
Discussion

Severe neonatal hyperbilirubinemia is a syndrome that affects approximately 1 million children every year, especially in low and middle-income countries (Olusanya et al., 2015). Many of the cases can be successfully treated with phototherapy to lower serum bilirubin levels but in more severe situations additional invasive methods are necessary to decrease bilirubin levels (Mitra and Rennie, 2017). OCA is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural agonist of the FXR with anticholestatic and hepatoprotective properties (Pellicciari et al., 2002). This compound has been used to treat patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) (Mudaliar et al., 2013). Patients that received 25mg or 50 mg of OCA for 6 weeks presented more sensibility to insulin and a reduction in inflammation and fibrosis biomarkers in liver (Mudaliar et al., 2013). In addition to being a drug that promotes benefits for patients with gastrointestinal diseases, we demonstrate that OCA is an effective alternative for the treatment of neonatal hyperbilirubinemia.

According to our RT-PCR data both bile acid pathways, classic and alternate, are downregulated in OCA treated neonatal mice, suggesting that these mice are producing less bile acid. This is consistent with other studies that demonstrate that mice treated with OCA presents a reduction of endogenous, primary, and secondary bile acids (Friedman et al., 2018). The suppression of endogenous bile acid by OCA leads to a change in the composition of the gut microbiota (Friedman et al., 2018). Another study has confirmed that the administration of OCA increases the abundance of \textit{Blautia} in the gut, which is an important bacterium linked to the metabolism of taurine-bound bile acid. This bile acid is abundant when mice are challenged with a high-fat diet while OCA has been shown to have a protective effect on NAFDL, a mechanism linked to the gut microbiome (Zhang et al., 2019).

The central function of FXR is to regulate the homeostasis of bile acids (Evans and Mangelsdorf, 2014). The crosstalk between small intestine and liver through FXR-FGF15/19
axis regulates the production of bile acids from cholesterol (Sinal et al., 2000). However, there is no evidence that FXR has a role in UGT1A1 induction. This was recently brought into question when it was shown that OCA treatment in adult patients with primary biliary cholangitis had the secondary effect of reducing serum bilirubin levels (Parés et al., 2020). Since bilirubin is selectively eliminated through UGT1A1 dependent glucuronidation, this clinical finding suggested that OCA was inducing UGT1A1 through an FXR dependent mechanism. To examine this possibility, OCA was administered to neonatal hUGT1 mice and serum bilirubin along with measurement of intestinal and liver UGT1A1 performed. It was confirmed that OCA treatment had a direct impact on activation of FXR, with resultant target genes in both the intestines and liver induced. OCA treatment led to a dramatic reduction in serum bilirubin, with significant induction of the intestinal UGT1A1 gene. While FXR target genes in the liver were induced, confirming that OCA had a direct impact on liver function, hepatic UGT1A1 was not induced. This was unusual since we have proven previously that activation of additional liver nuclear receptors, such as PXR (Chen et al., 2012), CAR (Yoda et al., 2017), PPARα (Seneko-Effenberger et al., 2007), and LXRα (Hansmann et al., 2020) are all capable of inducing liver UGT1A1. Thus, the inability of activated FXR in liver to induce UGT1A1 led us to speculate that OCA initiated induction of intestinal UGT1A1 was occurring through an independent mechanism not directly linked to FXR activation.

The induction of intestinal UGT1A1 by OCA catalyzes the metabolism of serum bilirubin, similar for what we have shown when intestinal UGT1A1 is induced following oral administration of other agents such as cadmium (Liu et al., 2016; Paszek and Tukey, 2020), arsenic (Liu et al., 2016), isothiocyanates (Yoda et al., 2017; Paszek and Tukey, 2020), and formula (Fujiwara et al., 2012). Induction of intestinal UGT1A1 is sufficient, in the absence of any regulation of liver UGT1A1, to metabolize and clear serum bilirubin. To examine the underlying mechanism of OCA induced intestinal UGT1A1, we examined a family of target genes that can be induced by activated nuclear receptors. From this initial screen, intestinal CYP2B10 was prominently
induced. In addition, induction of CYP2B10 by OCA only occurred in intestinal tissue, indicating the actions of OCA and induction of CYP2B10 are restricted to intestinal tissue, similar to what is observed for induction of intestinal UGT1A1. Both the human UGT1A1 and mouse Cyp2b10 genes can be induced by activated CAR. To examine the possible connection between OCA elicited CAR activation and induction of UGT1A1, OCA was administered to neonatal hUGT1/Car−/− mice followed by measurement of serum bilirubin and expression of UGT1A1 and CYP2B10. The absence of CAR function in hUGT1 mice resulted in limited clearance of serum bilirubin by OCA treatment and no induction of intestinal UGT1A1 and CYP2B10, confirming that the underlying mechanism of OCA induction of intestinal UGT1A1 is CAR dependent.

There is no evidence that OCA is a direct ligand for CAR, thus indicating that the induction of intestinal UGT1A1 through CAR dependency is occurring indirectly yet in an intestinal specific manner. One of the key functions of the intestinal tract is to continually renew IECs (Wang et al., 2017). IEC maturation stems from deep intestinal crypt cells proliferating and differentiating into the absorptive and secretory cell lineages that constitute the intestinal villi (Yeung et al., 2011; De Mey and Freund, 2013). The maturation process is tightly controlled through transcriptional repressive actions which include NCoR1, and if these repressive states are interrupted or released, accelerated proliferation and differentiation occurs (Mottis et al., 2013; Jo et al., 2015; Mennillo et al., 2020). We have currently established that the oral treatment of neonatal hUGT1 mice with isothiocyanates induces hepatic UGT1A1 through a CAR dependent mechanism that is directly linked to the development of hepatic oxidative stress (Yoda et al., 2017). However, this mechanism is not associated with CAR activation in either liver or intestines following OCA treatment. When we examined a series of selective intestinal maturation markers that are either induced or inhibited upon proliferation and differentiation, OCA led to induced neonatal maturation, a process that leads to induction of intestinal UGT1A1. With OCA inducing intestinal UGT1A1 in a CAR dependent manner, it was demonstrated that
accelerated IEC maturation following OCA treatment is also highly dependent on CAR, since IEC maturation or induction of UGT1A1 does not occur in hUGT1/Car<sup>−/−</sup> mice.

With our findings, we have developed a mechanistic model to explain the actions of OCA towards induction of intestinal UGT1A1 in hUGT1 mice (Fig. 7) As a potent FXR agonist, OCA activates FXR in both liver and intestinal tissue. This was confirmed by induction of FXR target genes in both tissues such as Shp, while FGF15 produced in the intestines blocks transcriptional activation of the Cyp7a1 gene in liver. Although FXR is activated in liver and intestines, OCA does not lead to the induction of liver UGT1A1, confirming that FXR as well as other potential nuclear receptors known to induce UGT1A1 such PXR, PPARα, LXRα and CAR are not activated in this tissue. However, intestinal UGT1A1 is significantly induced in the small intestine following OCA treatment. Associated with this induction is an absolute dependency on CAR, which is also tightly linked to IEC maturation. Since CAR is associated with UGT1A1 induction in small intestines and not liver, additional tissue specific factors associated with the intestines must be playing an important role in the activation of CAR, which also controls premature IEC maturation (Fig. 7).
Acknowledgments

Author Contributions

Designed the experiments: Weber, Tukey and Chen

Initial concept: van der Schoor and Jonker

Performed the experiments: Weber, Mennillo, and Yang

Wrote the manuscript: Weber and Tukey
References


Footnotes

Financial Support: This work was supported by the National Institutes of Health grants ES010337 and GM126074 (R.H.T) and R21-AI135677 (S.C.).
Figure legends

**Figure 1.** Induction of UGT1A1 by OCA in neonatal hUGT1 mice. Ten-day old neonatal hUGT1 mice were treated with 50 mg/kg OCA (divided in two doses of 25 mg/kg) or vehicle by p.o. administration for five consecutive days. (A) After the treatment, total serum bilirubin (TSB) levels were measure. (B) Liver and small intestine (SI) were used for gene and protein analysis. UGT1A1 gene expression was determined by RT- real time (Q) PCR and expressed as fold induction. (C) Western blots were performed from liver and SI tissue to examine UGT1A1 expression. The bands have been cropped and the full-length blots are in supplemental material. Values are the means of ± SD (n ≥ 3). Statistically significant differences between vehicle (Veh) and OCA are indicated by asterisks (Student t test: **P < 0.01).

**Figure 2.** Oral OCA effect in liver of hUGT1 mice. Litters were bred to produce hUGT1 mice and 10-day old neonatal mice treated with OCA or vehicle on day 10 followed by tissue preparation after treatment. (A) RNA was isolated from liver and used to conduct RT-qPCR for Cyp2b10, Shp and Cyp7a1 genes. Using total cell extracts from liver, Western blots were performed using antibodies toward mouse CYP2B10 and mouse CYP7A1. The bands have been cropped and the full-length blots are in supplemental material. (B) Total RNA was prepared from liver and RT-qPCR performed to measure expression of Cyp7a1, Cyp8b1, Cyp27a1 and Cyp7b1. Values are the means of ± SD (n ≥ 3). Statistically significant differences between vehicle (Veh) and OCA are indicated by asterisks (Student t test: *P < 0.05, ***P < 0.001).

**Figure 3.** Oral OCA treatment and effects in intestines of hUGT1 and hUGT1/Car−/− mice. Litters were bred to produce hUGT1 and hUGT1/Car−/− mice and 10-day old neonatal mice treated with OCA or vehicle on day 10, followed by tissue preparation after treatment. (A) After treatment, serum bilirubin levels were determined. (B) Intestinal UGT1A1 and Cyp2b10 gene expression was examined by RT-qPCR from OCA treated hUGT1 and hUGT1/Car−/− mice. From those same tissues, total cell extracts were prepared for Western blot analysis using anti-UGT1A1 and
anti-CYP2B10 antibodies. The bands have been cropped and the full-length blots are in supplemental material. Values are the means of ± SD (n ≥ 3). Statistically significant differences between vehicle (Veh) and OCA are indicated by asterisks (Student t test: *P < 0.05).

**Figure 4. OCA treatment promotes FXR target gene induction.** (A) Total RNA and cellular extracts were prepared from small intestine and liver of hUGT1 and hUGT1/Car<sup>-/-</sup> neonatal mice. (A) *Shp* and *Fgf15* gene expression from small intestines was determined by RT-qPCR. Cellular extracts were prepared for Western blot analysis to examine FGF15 protein expression. (B) Liver *Shp* and *Cyp7a1* gene expression was determined by RT-qPCR, while *Cyp7a1* protein expression was examined by Western blot analysis. The bands have been cropped and the full-length blots are in supplemental material. Values are the means of ± SD (n ≥ 3). Statistically significant differences between vehicle (Veh) and OCA are indicated by asterisks (Student t test: #P < 0.05; ##P < 0.01; between treatments).

**Figure 5. OCA treatment promotes intestinal maturation.** (A) Following OCA treatment, total RNA was prepared from small intestine of hUGT1 neonatal mice. *Sis*, *Krt20*, *Akp3*, *Glb1*, *Nox4* and *Lrp2* gene expression was determined by RT-qPCR. (B) Following OCA treatment to neonatal hUGT1 and hUGT1/Car<sup>-/-</sup> mice, small intestine RNA was used to examine *Sis*, *Akp3*, *Krt20*, *Npx4* and *Glb1* gene expression by RT-qPCR. From total cell extracts, Western blot analysis was performed using antibodies toward mouse SIS with P meaning precursor and M the mature form. Values are the means of ± SD (n ≥ 3). Statistically significant differences between vehicle (Veh) and OCA are indicated by asterisks (Student t test: *P < 0.05; **P < 0.01; ***P<0.001).

**Figure 6.** Treatment of intestinal organoids with OCA. Intestinal organoids cultured from neonatal hUGT1 intestinal tissue were treated with OCA and DAPT for 24 hours. (A) Gene expression of FXR target genes *Fgf15* and *Shp* by RT-qPCR. (B) *UGT1A1* gene expression and (C) *Cy2b10* gene expression. (D) Gene expression analysis of maturation marker genes *Sis*,
Akp3 and Krt20. (E) Western blot analysis of UGT1A1 and FGF15 following vehicle (VeH) or OCA treatment. The bands have been cropped and the full-length blots are in supplemental material. Values are the means of ± SD (n ≥ 3). Statistically significant differences between vehicle (Veh) and OCA are indicated by asterisks (Student t test: *P < 0.05; **P < 0.01; ***P<0.001).

Figure 7. Pathways involved with OCA treatment. Administration of OCA activates intestinal CAR and FXR, and their respective target genes. In small intestines, FXR activation leads to induction of FGF15 and Shp, while OCA is capable of inducing liver FXR target genes such as Shp gene expression. Induction of FGF15 results in inhibition of liver Cyp7a1 gene expression. Following oral OCA treatment, CAR becomes activated leading to an increase in intestinal epithelial cell maturation, as displayed by activation of specific marker genes. Activation of intestinal maturation results in induction of intestinal UGT1A1 that drives the metabolism of serum bilirubin.
Table 1. Primer sequences used for Reverse Transcription Quantitative-PCR (RT-qPCR).

<table>
<thead>
<tr>
<th>Primer</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human UGT1A1</td>
<td>5’-CCTTGCTCATCAAGATTTCTTC-3’</td>
<td>5’-ATTGATCCAAAGAGAAACCAC-3’</td>
</tr>
<tr>
<td>Mouse Cyp2b10</td>
<td>5’-AAAGTCGCCGTGGCAACCTCTC-3’</td>
<td>5’-CATCCAAAGTCTCTCATGG-3’</td>
</tr>
<tr>
<td>Mouse Nqo1</td>
<td>5’-TTAGGTGGTCCTTGGCAAC-3’</td>
<td>5’-GTCTTCTGTGAATGGGCGAC-3’</td>
</tr>
<tr>
<td>Mouse Cyp1a1</td>
<td>5’-AAAGTCCGTCGGCAACTTCC-3’</td>
<td>5’-CAGCTCCCATACTGCTGAC-3’</td>
</tr>
<tr>
<td>Mouse Cyp4a10</td>
<td>5’-TTAGGTCGGCAACCTCTCC-3’</td>
<td>5’-CAGCTCCCATACTGCTGAC-3’</td>
</tr>
<tr>
<td>Mouse Cyp3a11</td>
<td>5’-ACAAACAGCGAGGATGGAC-3’</td>
<td>5’-CCCATATCGGTAGAGGAGCA-3’</td>
</tr>
<tr>
<td>Mouse Cyclophilin</td>
<td>5’-CAGCGCCACTGTCGCTT-3’</td>
<td>5’-TGCTTTGGAACTTTGTCTGC-3’</td>
</tr>
<tr>
<td>Mouse Shp</td>
<td>5’-CAGATCCCTTCATTCCAACCCAG-3’</td>
<td>5’-AAGACTTCACACAGTGCACCA-3’</td>
</tr>
<tr>
<td>Mouse Fgf15</td>
<td>5’-CAGTTCTTCTCCCGAGATGGG-3’</td>
<td>5’-TGAAGACGATGGCCCATCAAG-3’</td>
</tr>
<tr>
<td>Mouse Cyp7a1</td>
<td>5’-GGGAATGCCATCTTACTTGGA-3’</td>
<td>5’-TCCCTTAGCAGATGGCCAAGA-3’</td>
</tr>
<tr>
<td>Mouse Cyp8b1</td>
<td>5’-GATTGGGAAAGAGGAGACCACC-3’</td>
<td>5’-TCCCTTAGCAGATGGCCAAGA-3’</td>
</tr>
<tr>
<td>Mouse Cyp27a1</td>
<td>5’-GAGGAACCTGCAATTCACGACA-3’</td>
<td>5’-CTATGCTGTGACCTTGGCCCA-3’</td>
</tr>
<tr>
<td>Mouse Cyp7b1</td>
<td>5’-TTATCAAGGGGTGTTTACGCA-3’</td>
<td>5’-TCCTAGGCTCTTCTTTGACC-3’</td>
</tr>
<tr>
<td>Mouse Akp3</td>
<td>5’-CTGCAGCCCTACACCCAGCT-3’</td>
<td>5’-AGGCTTCTGCGCCTTAT-3’</td>
</tr>
<tr>
<td>Mouse Sis</td>
<td>5’-ACCCCTAGTCTGCGAGGTG-3’</td>
<td>5’-CACATTGCTTGGCTTGGATGC-3’</td>
</tr>
<tr>
<td>Mouse Krt20</td>
<td>5’-CTGCGAGAACATGCTGAACG-3’</td>
<td>5’-CTTGGAGATCAGCTCCTCC-3’</td>
</tr>
<tr>
<td>Mouse Glb1</td>
<td>5’-ACTGCTGCAACTGCTTGG-3’</td>
<td>5’-ATGTATCGGAGAATGGCTCC-3’</td>
</tr>
<tr>
<td>Mouse Lrp2</td>
<td>5’-CCAGGATTTCGGTGATGAGG-3’</td>
<td>5’-CGGGAACCTCACTGACAACT-3’</td>
</tr>
<tr>
<td>Mouse Nox4</td>
<td>5’-TCCTGGAAACCTTCTGCTG-3’*</td>
<td>5’-CGGGAACCATAGGTAAAAGGA-3’</td>
</tr>
</tbody>
</table>
Figure 2

A

Cyp2b10

*  

\[
\begin{array}{c}
\text{Veh} \quad \text{OCA} \\
1.0 \quad 0.5 \\
1.5 \quad 1.0 \\
2.0 \quad 2.0 \\
\end{array}
\]

Shp

*  

\[
\begin{array}{c}
\text{Veh} \quad \text{OCA} \\
1.0 \quad 1.5 \\
2.0 \quad 4.0 \\
3.0 \quad 0.0 \\
\end{array}
\]

Cyp7a1

***  

\[
\begin{array}{c}
\text{Veh} \quad \text{OCA} \\
0.0 \quad 0.5 \\
1.0 \quad 1.5 \\
2.0 \quad 4.0 \\
\end{array}
\]

B

\[
\begin{array}{c}
\text{Veh} \quad \text{OCA} \\
0.0 \quad 4.0 \\
1.0 \quad 2.0 \\
2.0 \quad 3.0 \\
3.0 \quad 4.0 \\
\end{array}
\]

C

\[
\begin{array}{c}
\text{Veh} \quad \text{OCA} \\
1 \quad 1 \quad 2 \quad 3 \\
1 \quad 2 \quad 3 \\
\end{array}
\]

CYP2B10

CYP7A1

GAPDH
Figure 6

A. **Fgf15**, **Shp**

B. **UGT1A1**

C. **Cyp2b10**

D. **Sis**, **Krt20**, **Akp3**

E. Western blot analysis of **UGT1A1**, **FGF15**, and **GAPDH**
Figure 7

Obeticholic Acid (OCA)

Liver ↔ Small Intestines → FXR

Liver ↔ FGF15

FXR → CAR

↑ Sis, Akp3, Krt2, Shp, FGF15

↓ Nox4

Intestinal Maturation

↑ UGT1A1, ↓ TSB

↓ CYP7A1

↓ Shp